Schwimmer J A, Markowitz G S, Valeri A M, Imbriano L J, Alvis R, D'Agati V D
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Clin Nephrol. 2003 Oct;60(4):233-41.
Secondary focal segmental glomerulosclerosis (FSGS) is a pattern of glomerular injury mediated by hyperfiltration and other adaptive structural-functional responses. We describe 3 non-obese patients with elevated body mass index (BMI) owing to increased muscle mass who had renal biopsy findings favoring a form of secondary FSGS.
Clinical and pathologic data were obtained on 3 patients with 1) renal biopsy findings of focal segmental and/or global glomerulosclerosis with glomerulomegaly; 2) BMI > or = 30; 3) body fat percentage < 20%; 4) "highly muscular" appearance, and 5) proteinuria > or = 1 g/d without nephrotic syndrome. 24-hour urine creatinine excretion was used to estimate lean body mass and percentage body fat.
The 3 patients were males (age 38 - 48 years) employed in jobs requiring strenuous physical activity. BMIs ranged from 30.4 - 32.1 kg/m2 with body fat percentages of 12.9 - 16.8%. Creatinine clearances at time of biopsy ranged from 113 - 208 ml/min. Renal biopsies showed focal segmental and/or global glomerulosclerosis affecting a minority of glomeruli with glomerular hypertrophy and minimal (mean 15%) foot process effacement. Treatments included angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or weight loss. Over a mean follow-up time of 24.3 months, serum creatinine remained stable and proteinuria decreased in all patients.
Non-obese patients with increased BMI due to elevated muscle mass are at risk of developing a secondary form of FSGS that resembles obesity-related glomerulopathy.
继发性局灶节段性肾小球硬化(FSGS)是一种由超滤及其他适应性结构 - 功能反应介导的肾小球损伤模式。我们描述了3例非肥胖患者,其体重指数(BMI)升高是由于肌肉量增加,肾活检结果支持一种继发性FSGS形式。
获取了3例患者的临床和病理数据,这些患者具有以下特征:1)肾活检显示局灶节段性和/或全球性肾小球硬化伴肾小球肿大;2)BMI≥30;3)体脂百分比<20%;4)“肌肉发达”外观;5)蛋白尿≥1 g/d且无肾病综合征。采用24小时尿肌酐排泄量来估计瘦体重和体脂百分比。
这3例患者均为男性(年龄38 - 48岁),从事需要剧烈体力活动的工作。BMI范围为30.4 - 32.1 kg/m²,体脂百分比为12.9 - 16.8%。活检时的肌酐清除率范围为113 - 208 ml/min。肾活检显示局灶节段性和/或全球性肾小球硬化,累及少数肾小球,伴有肾小球肥大,足突消失最少(平均15%)。治疗方法包括使用血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂或减重。在平均24.3个月的随访时间内,所有患者的血清肌酐保持稳定,蛋白尿减少。
因肌肉量增加导致BMI升高的非肥胖患者有发生类似于肥胖相关肾小球病的继发性FSGS的风险。